IMVT News and Press, Immunovant Inc. From 11/04/22

IMVT-1402, a next generation, subcutaneously administered, neonatal fragment crystallizable receptor (FcRn) inhibitor unveiled New development programs for batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease announced Phase 3 t...

Summary Shares have lost roughly half their value since arriving on the Nasdaq in late 2019 via SPAC. Anti-FcRn space is increasingly attractive with 20+ indications on deck or being pursued by leaders Argenx and Janssen. IMVT-1402 could offer best-in-class IgG reductions with...

Shares of Immunovant (NASDAQ: IMVT) were skyrocketing 75.1% higher this week as of 3:42 p.m. ET on Thursday, according to data provided by S&P Global Market Intelligence . Most of this big gain came after the company announced a public offering on Tuesday to sell 12.5 millio...

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all cancer-related deaths worldwide. Of concern, despite treatmen...

Immunovant ( NASDAQ: IMVT ) has priced 12.5M shares of its common stock at $6.00 per share, for total gross proceeds of $75M. Investors who have agreed to purchase shares in the offering include Logos Capital, Deep Track Capital, Frazier Life Sciences, TCGX, BVF Partners L...

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at...

Immunovant, Inc. ( NASDAQ: IMVT ), a biotech focused on autoimmune diseases, gained 20% Thursday as Wall Street reacted to IMVT-1402, its latest addition to the therapeutic portfolio unveiled at Roivant’s Investor Day on Sep. 28. IMVT-1402 offers IgG reduction...

In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. Plan to submit IND and initiate Phase 1 study in early 2023 with initial data expected in mid-2023. Previously announced pro...

Shares of small-cap clinical-stage biotech Immunovant ( NASDAQ: IMVT ) fell as much as 12.7% to $4.26 in Monday morning trading, after UBS research downgraded its rating on the company to neutral from buy, citing a lack of major clinical analysts until H2 of next year. I...

NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will present a corporate up...